<DOC>
	<DOCNO>NCT01797965</DOCNO>
	<brief_summary>The primary objective study assess safety tolerability long-term treatment BIIB019 ( Daclizumab High Yield Process ; DAC HYP ) monotherapy participant relapse remit multiple sclerosis ( RRMS ) complete Study 205MS301 ( NCT01064401 ) , Study 205MS203 ( NCT01051349 ) Study 205MS302 ( NCT01462318 ) . Secondary objective study study population follow : To describe MS-related outcome , include MS relapse , disability progression , MS lesion formation , participant-reported impact MS , follow long-term treatment DAC HYP To assess long-term immunogenicity DAC HYP administer prefilled syringe ( PFS ) To assess safety , tolerability , efficacy switch DAC HYP participants previously long-term treatment interferon Î²-1a ( Avonex ) Study 205MS301 ( NCT01064401 ) .</brief_summary>
	<brief_title>Long-Term Extension Study Participants With Multiple Sclerosis Who Have Completed Study 205MS301 ( NCT01064401 ) Evaluate Safety Efficacy BIIB019</brief_title>
	<detailed_description>Enrollment include 1600 Participants , include approximately 1200 Participants complete Study 205MS301 ( NCT01064401 ) . Additionally , approximately 400 Participants BIIB019 extension study 205MS203 ( NCT01051349 ) 205MS302 ( NCT01462318 ) eligible enter Study 205MS303 Week 144 Study 205MS303 [ Study 205MS301 ( NCT01064401 ) , study 205MS203 ( NCT01051349 ) study 205MS302 ( NCT01462318 ) refer parent study protocol ] . All Participants receive dose DAC HYP receive parent study ; i.e. , 150 mg SC injection every 4 week . The duration DAC HYP treatment approximately 5 year , availability commercial product ( whichever sooner ) .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Daclizumab</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>Key Must subject currently participate Study 205MS301 ( NCT01064401 ) , subject currently participate Study 205MS203 ( NCT01051349 ) Study 205MS302 ( NCT01462318 ) complete End Study Visit ( Week 96 later ) . Women childbearing potential must practice effective contraception study willing able continue contraception 4 month last dose study treatment . Key Any subject permanently discontinue study treatment Study 205MS301 ( NCT01064401 ) , Study 205MS203 ( NCT01051349 ) Study 205MS302 ( NCT01462318 ) prior end study treatment period , Early Termination visit Study 205MS301 , Study 205MS203 ( NCT01051349 ) Study 205MS302 ( NCT01462318 ) . Any significant change subject 's medical history would preclude administration BIIB019 , include laboratory test current clinically significant condition , opinion Investigator , would exclude subject 's participation Study 205MS301 ( NCT01064401 ) , Study 205MS203 ( NCT01051349 ) Study 205MS302 ( NCT01462318 ) . The Investigator must review subject 's medical fitness participation consider factor would preclude treatment Study 205MS303 . NOTE : Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>